Trial Profile
A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara(TM) (Ustekinumab) in The Treatment of Scalp Psoriasis.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 17 Jul 2012 Planned initiation date changed from 1 Apr 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 26 Mar 2012 New trial record